Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab

Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab

Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2024-11
Hauptverfasser: Mei, Rena, Pepe, Emily, Oh, David Y, Tsai, Katy K, Chugh, Rishika, Kattah, Michael G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Inflammatory bowel diseases
container_volume
creator Mei, Rena
Pepe, Emily
Oh, David Y
Tsai, Katy K
Chugh, Rishika
Kattah, Michael G
description Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.
doi_str_mv 10.1093/ibd/izae259
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3123807758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3123807758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-e187dea3741c37b5ec45d8b224a7abd46914ddccdfa05f344913ddac03dacec3</originalsourceid><addsrcrecordid>eNo9kNFLwzAQxoMobk6ffJc-ClKXNMnSPMqYOhgIbuBjSZPUxi1JbVJh--uNOOXg7r7jx8fxAXCN4D2CHE9NrabmIHRB-QkYI4pnOSkJOU07ZGUOOS9H4CKEDwiLVPwcjDAnnELKxqBZ720XvRXRyEw4la298--96Nqkl7br_Ze22sXMN0nawels3mq57bxJx6VrTW2i77OFi7r30u9MNCF7M7HNXk0QbmsOgxX1JThrxC7oq-OcgM3jYjN_zlcvT8v5wyqXBSIx16hkSgvMCJKY1VRLQlVZFwURTNSKzDgiSkmpGgFpgwnhCCslJMSpaYkn4PbXNv39OegQK2uC1LudcNoPocKowCVkjJYJvftFZe9D6HVTdb2xot9XCFY_uVYp1-qYa6JvjsZDbbX6Z_-CxN-L7Xgi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3123807758</pqid></control><display><type>article</type><title>Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Mei, Rena ; Pepe, Emily ; Oh, David Y ; Tsai, Katy K ; Chugh, Rishika ; Kattah, Michael G</creator><creatorcontrib>Mei, Rena ; Pepe, Emily ; Oh, David Y ; Tsai, Katy K ; Chugh, Rishika ; Kattah, Michael G</creatorcontrib><description>Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.</description><identifier>ISSN: 1078-0998</identifier><identifier>ISSN: 1536-4844</identifier><identifier>EISSN: 1536-4844</identifier><identifier>DOI: 10.1093/ibd/izae259</identifier><identifier>PMID: 39495057</identifier><language>eng</language><publisher>England</publisher><ispartof>Inflammatory bowel diseases, 2024-11</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c214t-e187dea3741c37b5ec45d8b224a7abd46914ddccdfa05f344913ddac03dacec3</cites><orcidid>0000-0001-5436-1977 ; 0000-0003-4175-7889 ; 0000-0002-6067-6585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39495057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mei, Rena</creatorcontrib><creatorcontrib>Pepe, Emily</creatorcontrib><creatorcontrib>Oh, David Y</creatorcontrib><creatorcontrib>Tsai, Katy K</creatorcontrib><creatorcontrib>Chugh, Rishika</creatorcontrib><creatorcontrib>Kattah, Michael G</creatorcontrib><title>Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab</title><title>Inflammatory bowel diseases</title><addtitle>Inflamm Bowel Dis</addtitle><description>Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.</description><issn>1078-0998</issn><issn>1536-4844</issn><issn>1536-4844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kNFLwzAQxoMobk6ffJc-ClKXNMnSPMqYOhgIbuBjSZPUxi1JbVJh--uNOOXg7r7jx8fxAXCN4D2CHE9NrabmIHRB-QkYI4pnOSkJOU07ZGUOOS9H4CKEDwiLVPwcjDAnnELKxqBZ720XvRXRyEw4la298--96Nqkl7br_Ze22sXMN0nawels3mq57bxJx6VrTW2i77OFi7r30u9MNCF7M7HNXk0QbmsOgxX1JThrxC7oq-OcgM3jYjN_zlcvT8v5wyqXBSIx16hkSgvMCJKY1VRLQlVZFwURTNSKzDgiSkmpGgFpgwnhCCslJMSpaYkn4PbXNv39OegQK2uC1LudcNoPocKowCVkjJYJvftFZe9D6HVTdb2xot9XCFY_uVYp1-qYa6JvjsZDbbX6Z_-CxN-L7Xgi</recordid><startdate>20241104</startdate><enddate>20241104</enddate><creator>Mei, Rena</creator><creator>Pepe, Emily</creator><creator>Oh, David Y</creator><creator>Tsai, Katy K</creator><creator>Chugh, Rishika</creator><creator>Kattah, Michael G</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5436-1977</orcidid><orcidid>https://orcid.org/0000-0003-4175-7889</orcidid><orcidid>https://orcid.org/0000-0002-6067-6585</orcidid></search><sort><creationdate>20241104</creationdate><title>Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab</title><author>Mei, Rena ; Pepe, Emily ; Oh, David Y ; Tsai, Katy K ; Chugh, Rishika ; Kattah, Michael G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-e187dea3741c37b5ec45d8b224a7abd46914ddccdfa05f344913ddac03dacec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mei, Rena</creatorcontrib><creatorcontrib>Pepe, Emily</creatorcontrib><creatorcontrib>Oh, David Y</creatorcontrib><creatorcontrib>Tsai, Katy K</creatorcontrib><creatorcontrib>Chugh, Rishika</creatorcontrib><creatorcontrib>Kattah, Michael G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammatory bowel diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mei, Rena</au><au>Pepe, Emily</au><au>Oh, David Y</au><au>Tsai, Katy K</au><au>Chugh, Rishika</au><au>Kattah, Michael G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab</atitle><jtitle>Inflammatory bowel diseases</jtitle><addtitle>Inflamm Bowel Dis</addtitle><date>2024-11-04</date><risdate>2024</risdate><issn>1078-0998</issn><issn>1536-4844</issn><eissn>1536-4844</eissn><abstract>Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.</abstract><cop>England</cop><pmid>39495057</pmid><doi>10.1093/ibd/izae259</doi><orcidid>https://orcid.org/0000-0001-5436-1977</orcidid><orcidid>https://orcid.org/0000-0003-4175-7889</orcidid><orcidid>https://orcid.org/0000-0002-6067-6585</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0998
ispartof Inflammatory bowel diseases, 2024-11
issn 1078-0998
1536-4844
1536-4844
language eng
recordid cdi_proquest_miscellaneous_3123807758
source Oxford University Press Journals All Titles (1996-Current)
title Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A57%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptomatic%20and%20Sonographic%20Improvement%20of%20Immune%20Checkpoint%20Inhibitor%20Enterocolitis%20With%20Risankizumab&rft.jtitle=Inflammatory%20bowel%20diseases&rft.au=Mei,%20Rena&rft.date=2024-11-04&rft.issn=1078-0998&rft.eissn=1536-4844&rft_id=info:doi/10.1093/ibd/izae259&rft_dat=%3Cproquest_cross%3E3123807758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3123807758&rft_id=info:pmid/39495057&rfr_iscdi=true